Synopsis
Synopsis
0
CEP/COS
0
NDC API
0
VMF
0
EDQM
0
USP
0
JP
0
Others
0
FDA Orange Book
0
Canada
0
Australia
0
South Africa
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
US Medicaid
NA
Annual Reports
NA
Regulatory FDF Prices
NA
0
FDF
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. Benfothiamine
2. Benphothiamine
3. Btmp-benfo
4. Milgamma
5. Neurostop
6. S-benzoylthiamine Monophosphate
1. 22457-89-2
2. Benphothiamine
3. Betivina
4. Benzoylthiamine Monophosphate
5. S-benzoylthiamine O-monophosphate
6. S-benzoylthiamine Monophosphate
7. Benfotiamina
8. Benfotiaminum
9. 22457-89-2 (free Acid)
10. S-[(z)-2-[(4-amino-2-methylpyrimidin-5-yl)methyl-formylamino]-5-phosphonooxypent-2-en-3-yl] Benzenecarbothioate
11. (z)-s-(2-(n-((4-amino-2-methylpyrimidin-5-yl)methyl)formamido)-5-(phosphonooxy)pent-2-en-3-yl) Benzothioate
12. S-[2-{[(4-amino-2-methylpyrimidin-5-yl)methyl](formyl)amino}-5-(phosphonooxy)pent-2-en-3-yl] Benzenecarbothioate
13. Sr-01000872627
14. N-((4-amino-2-methyl-5-pyrimidinyl)methyl)-n-(4-hydroxy-2-mercapto-1-methyl-1-butenyl)formamide S-benzoate O-phosphate
15. Chebi:41039
16. Prestwick_68
17. Biotamin (tn)
18. Mfcd00057343
19. Prestwick2_000654
20. Prestwick3_000654
21. Benfotiamine (jan/inn)
22. Bspbio_000687
23. Schembl188070
24. Bpbio1_000757
25. Chembl4303665
26. Schembl19184708
27. Hms1570c09
28. Hms2097c09
29. Hms3714c09
30. Zinc2015559
31. Stl453586
32. Akos015920320
33. Ac-8280
34. Ccg-220654
35. Db11748
36. Ncgc00179477-01
37. (3z)-4-{n-[(4-amino-2-methylpyrimidin-5-yl)methyl]carbonylamino}-3-(phenylcarb Onylthio)pent-3-enyl Dihydrogen Phosphate
38. 57b892
39. A15020
40. D01255
41. Sr-01000872627-1
42. Sr-01000872627-2
43. 137-74-6
44. S-[(2z)-2-{[(4-amino-2-methylpyrimidin-5-yl)methyl](formyl)amino}-5-(phosphonooxy)pent-2-en-3-yl] Benzenecarbothioate
45. S-{(1z)-2-[[(4-amino-2-methyl-5-pyrimidinyl)methyl](formyl)amino]-1-[2-(phosphonooxy)ethyl]-1-propenyl} Benzenecarbothioate
46. S-{(1z)-2-[[(4-amino-2-methyl-5-pyrimidinyl)methyl](formyl)amino]-1-[2-(phosphonooxy)ethyl]-1-propenyl} Benzenecarbothioate, Aldrichcpr
| Molecular Weight | 466.4 g/mol |
|---|---|
| Molecular Formula | C19H23N4O6PS |
| XLogP3 | 0.5 |
| Hydrogen Bond Donor Count | 3 |
| Hydrogen Bond Acceptor Count | 10 |
| Rotatable Bond Count | 10 |
| Exact Mass | 466.10759264 g/mol |
| Monoisotopic Mass | 466.10759264 g/mol |
| Topological Polar Surface Area | 181 Ų |
| Heavy Atom Count | 31 |
| Formal Charge | 0 |
| Complexity | 697 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 1 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Adjuvants, Immunologic
Substances that augment, stimulate, activate, potentiate, or modulate the immune response at either the cellular or humoral level. The classical agents (Freund's adjuvant, BCG, Corynebacterium parvum, et al.) contain bacterial antigens. Some are endogenous (e.g., histamine, interferon, transfer factor, tuftsin, interleukin-1). Their mode of action is either non-specific, resulting in increased immune responsiveness to a wide variety of antigens, or antigen-specific, i.e., affecting a restricted type of immune response to a narrow group of antigens. The therapeutic efficacy of many biological response modifiers is related to their antigen-specific immunoadjuvanticity. (See all compounds classified as Adjuvants, Immunologic.)
Chelating Agents
Chemicals that bind to and remove ions from solutions. Many chelating agents function through the formation of COORDINATION COMPLEXES with METALS. (See all compounds classified as Chelating Agents.)
A - Alimentary tract and metabolism
A11 - Vitamins
A11D - Vitamin b1, plain and in combination with vitamin b6 and b12
A11DA - Vitamin b1, plain
A11DA03 - Benfotiamine
API SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
USDMF
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]EU WC
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Listed Suppliers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]API Reference Price
API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
| Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
|---|
Upgrade, download data, analyse, strategize, subscribe with us 
Drugs in Development
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]INTERMEDIATE SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDF Dossiers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Digital Content
NEWS #PharmaBuzz
Market Place
ANALYTICAL
Analytical Methods
ABOUT THIS PAGE
97
PharmaCompass offers a list of Benfotiamine API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Benfotiamine manufacturer or Benfotiamine supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Benfotiamine manufacturer or Benfotiamine supplier.
PharmaCompass also assists you with knowing the Benfotiamine API Price utilized in the formulation of products. Benfotiamine API Price is not always fixed or binding as the Benfotiamine Price is obtained through a variety of data sources. The Benfotiamine Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Benfotiaminum [INN-Latin] manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Benfotiaminum [INN-Latin], including repackagers and relabelers. The FDA regulates Benfotiaminum [INN-Latin] manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Benfotiaminum [INN-Latin] API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Benfotiaminum [INN-Latin] manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Benfotiaminum [INN-Latin] supplier is an individual or a company that provides Benfotiaminum [INN-Latin] active pharmaceutical ingredient (API) or Benfotiaminum [INN-Latin] finished formulations upon request. The Benfotiaminum [INN-Latin] suppliers may include Benfotiaminum [INN-Latin] API manufacturers, exporters, distributors and traders.
click here to find a list of Benfotiaminum [INN-Latin] suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Benfotiaminum [INN-Latin] DMF (Drug Master File) is a document detailing the whole manufacturing process of Benfotiaminum [INN-Latin] active pharmaceutical ingredient (API) in detail. Different forms of Benfotiaminum [INN-Latin] DMFs exist exist since differing nations have different regulations, such as Benfotiaminum [INN-Latin] USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Benfotiaminum [INN-Latin] DMF submitted to regulatory agencies in the US is known as a USDMF. Benfotiaminum [INN-Latin] USDMF includes data on Benfotiaminum [INN-Latin]'s chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Benfotiaminum [INN-Latin] USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Benfotiaminum [INN-Latin] suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The Benfotiaminum [INN-Latin] Drug Master File in Japan (Benfotiaminum [INN-Latin] JDMF) empowers Benfotiaminum [INN-Latin] API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the Benfotiaminum [INN-Latin] JDMF during the approval evaluation for pharmaceutical products. At the time of Benfotiaminum [INN-Latin] JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of Benfotiaminum [INN-Latin] suppliers with JDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a Benfotiaminum [INN-Latin] Drug Master File in Korea (Benfotiaminum [INN-Latin] KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Benfotiaminum [INN-Latin]. The MFDS reviews the Benfotiaminum [INN-Latin] KDMF as part of the drug registration process and uses the information provided in the Benfotiaminum [INN-Latin] KDMF to evaluate the safety and efficacy of the drug.
After submitting a Benfotiaminum [INN-Latin] KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Benfotiaminum [INN-Latin] API can apply through the Korea Drug Master File (KDMF).
click here to find a list of Benfotiaminum [INN-Latin] suppliers with KDMF on PharmaCompass.
A Benfotiaminum [INN-Latin] written confirmation (Benfotiaminum [INN-Latin] WC) is an official document issued by a regulatory agency to a Benfotiaminum [INN-Latin] manufacturer, verifying that the manufacturing facility of a Benfotiaminum [INN-Latin] active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Benfotiaminum [INN-Latin] APIs or Benfotiaminum [INN-Latin] finished pharmaceutical products to another nation, regulatory agencies frequently require a Benfotiaminum [INN-Latin] WC (written confirmation) as part of the regulatory process.
click here to find a list of Benfotiaminum [INN-Latin] suppliers with Written Confirmation (WC) on PharmaCompass.
Benfotiaminum [INN-Latin] Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Benfotiaminum [INN-Latin] GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Benfotiaminum [INN-Latin] GMP manufacturer or Benfotiaminum [INN-Latin] GMP API supplier for your needs.
A Benfotiaminum [INN-Latin] CoA (Certificate of Analysis) is a formal document that attests to Benfotiaminum [INN-Latin]'s compliance with Benfotiaminum [INN-Latin] specifications and serves as a tool for batch-level quality control.
Benfotiaminum [INN-Latin] CoA mostly includes findings from lab analyses of a specific batch. For each Benfotiaminum [INN-Latin] CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Benfotiaminum [INN-Latin] may be tested according to a variety of international standards, such as European Pharmacopoeia (Benfotiaminum [INN-Latin] EP), Benfotiaminum [INN-Latin] JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Benfotiaminum [INN-Latin] USP).
